• Hengrui Pharma will present 64 research findings at the ESMO Congress in Madrid, Oct. 23-27, 2026.
• Presentations will include phase 3 results for HER2-targeted trastuzumab rezetecan in advanced breast cancer and HER3-targeted ruzaltatug rezetecan in advanced lung cancer.
• Positive ruzaltatug rezetecan trial results supported China's acceptance of its marketing application for previously treated EGFR-mutated advanced lung cancer in July 2026.
• Trastuzumab rezetecan's HORIZON-Breast06 study will assess its therapeutic potential in HER2-low advanced breast cancer.
• Preliminary phase 2 results will cover KRAS G12D inhibitor HRS-4642 with chemotherapy, with or without adebrelimab, as perioperative pancreatic cancer treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN76419) on October 21, 2026, and is solely responsible for the information contained therein.